Results show 74% of patients were able to stop taking and remain off proton pump inhibitor medications at 12-month follow up SAN MATEO, Calif. (February 20, 2014)–EndoGastric Solutions® (EGS), the leader in endoluminal reconstructive treatment for Gastroesophageal...
SAN MATEO, Calif. (February 19, 2014)–EndoGastric Solutions® (EGS), the leader in endoluminal reconstructive treatment for gastroesophageal reflux disease, announced today that it has reached a civil settlement with the U.S. Department of Justice related to...
Randomized, head-to-head study represents most comprehensive effort to date to compare Transoral Incisionless Fundoplication (TIF®) outcomes to sham surgery and PPI therapy in patients with GERD Company also announces 14,000 patients treated with TIF procedure since...
TEMPO Study Level 1 Data Directly Comparing Transoral Incisionless Fundoplication (TIF) Procedure to PPI Use Presented at DDW® 2013 Redwood City, CA (May 21, 2013)–EndoGastric Solutions® (EGS), the leader in endoluminal reconstructive treatment for gastroesophageal...
